In a quarterly disclosure filed with the SEC, it was revealed that Robert Olstein's firm, Olstein Capital Management, has completely divested its holdings in Thermo Fisher Scientific (TMO). This report, which covers the trading period that ended on June 30, 2026, shows the sale of all 6,750 shares. It is important to remember that these 13F filings are submitted with a delay and do not reflect real-time trading activity.
The exit from Thermo Fisher coincides with the acquisition of Olstein Capital Management's mutual fund business by Easterly Asset Management, which was finalized on June 29, 2026. This major business transition for the firm likely prompted the liquidation of many holdings, including the stake in Thermo Fisher. During the same period, Thermo Fisher reported strong second-quarter financial results and showcased new capabilities in manufacturing and research.